OBJECTIVES: Chronic disease imparts significant disability, premature mortality and economic burden on countries. Chronic obstructive pulmonary disease (COPD) will be the fifth leading cause of disability-adjusted mortality in 2020. Causative exposures include tobacco smoke, biomass fuels, occupational and other environmental factors. The Burden of Obstructive Lung Disease (BOLD) project will estimate the prevalence and burden of COPD globally. Here, we on the design, development and application of a population simulation model to forecast country-specific economic burden of COPD. To show feasibility of the model, we report US burden data. METHODS: A publicly available population simulation model was developed to estimate annual and future mortality and costs. The model reflects changes in the size, composition and population demographics of the jurisdiction. Input data include disease prevalence from the BOLD COPD epidemiology studies, tobacco smoking and cessation rates, background mortality, disease attributable mortality, annual incidence of COPD, lung function progression data from the Framingham Heart Study and costs. Simulations are based on a starting cohort age 20 years and older in 2005. Five, 10 and 20-year projections are discounted at 3% per year.

RESULTS: The model projects COPD prevalence to increase each year. In 2005, the projected cost of COPD in the US was $51.4 billion in medical expenses or $256 per capita. Cumulative discounted 5, 10 and 20 year medical costs for COPD were $304.9 billion, $678.4 billion and $1415.3 billion. CONCLUSIONS: COPD is one of the world’s leading causes of disability and mortality. The economic consequences of tobacco use and occupational exposures leading to COPD are substantial. We developed this model as part of a global burden identification and reduction project. Here, we show its application for burden simulation with US data, but intend a larger global effort in conjunction with the BOLD project.

COST ANALYSIS OF HEALTH CARE RESOURCE UTILIZATION DURING TREATMENT FOR RESPIRATORY TRACK INFECTIONS (RTIS) WITH TELITHROMYCIN OR CLARITHROMYCIN OR AMOXICILLIN/CLAVULANIC ACID IN GREECE

Aneli A1, Maniadakis N2
1Sanofi Aventis Greece, Athens, Athens, Greece; 2University Hospital of Heraklion, Crete, Greece

OBJECTIVES: To compare direct medical costs related to the management of community acquired pneumonia (CAP) and acute exacerbations of chronic bronchitis (AECB) between telithromycin (TEL) and clarithromycin (CLA) or amoxicillin/clavulanic acid (AMC), in both public and private sector in Greece. METHODS: A health outcomes model was developed from three Phase III multinational clinical studies comparing TEL with CLA in CAP, and with AMC in AECB. In each study patients were followed for 36 days and the primary endpoint was clinical efficacy at post therapy visit. Health care resources included in the model were additional non-protocol antibiotics, hospitalizations, laboratory tests and outpatient health care professional visits. Two cost analyses were performed; one from the perspective of Greek Health care System by using public sector unit costs and one from private sector perspective in Greece (including both reimbursable costs and out of pocket costs) in an effort to present a more realistic case for Greece. RESULTS: From the Greek Health care System perspective, the use of TEL instead of CLA in CAP resulted in cost savings of up to €49 per patient and up to €20 per patient when compared with AMC in AECB. For the Greek private sector, TEL cost differences were even greater, up to €71 when administered for CAP instead of CLA and up to €28 in AECB instead of AMC.

The cost savings resulted from TEL patients required fewer non-protocol additional health care resources (mainly a lower rate of hospitalization and shorter length of stay) than the patients in the comparator groups in both CAP and AECB.

CONCLUSION: In Greece the use of telithromycin as a first line treatment option for CAP and AECB instead of clarithromycin or amoxicillin/clavulanic acid respectively, may significantly reduce health care costs in both public and private sector.

OUTCOMES, RESOURCE CONSUMPTION AND COSTS OF INTENSIVE CARE PATIENTS HOSPITALIZED WITH ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN THE USA AND CANADA

Eichmann F1, Reiberger U1, Caeser M2
1Kendle GmbH & Co GMI KG, München, Germany; 2Altana Pharma AG, Konstanz, Germany

OBJECTIVES: To describe ARDS patients regarding survival, ventilation status, predisposing events, disease characteristics, length of hospital stay and duration of ventilation. METHODS: In a phase III clinical trial investigating treatment with Venticate (rSPC surfactant) compared to standard treatment in patients hospitalized for ARDS (NEJM 351, 884–892, 2004), patients were followed up for up to one year after randomization. This analysis is focused on the initial hospitalization and describes the pooled results from both treatment groups. Data were collected for 197 patients by means of a specific questionnaire covering